search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Pneumococcal immune response to Synflorix® or Prevenar-13® in infants.


- candidate number10350
- NTR NumberNTR3069
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR15-sep-2011
- Secondary IDsVAC-259 Vaccinology
- Public TitlePneumococcal immune response to Synflorix® or Prevenar-13® in infants.
- Scientific TitleDevelopment of humoral and cellular immune response in infants after pneumococcal conjugate vaccinations with Synflorix® or Prevenar-13®.
- ACRONYMPIEN
- hypothesisSynflorix (PCV10) and Prevenar-13 (PCV13) are comparable in inducing cellular and humoral immune responses in Dutch infants for the 10 overlapping serotypes in the vaccines. Differences are expected for three serotypes that are present in Prevenar-13 but absent in Synflorix.
- Healt Condition(s) or Problem(s) studiedInfectious diseases, Pneumococcal vaccination, Streptococcus pneumonia
- Inclusion criteria1. The children have to be of normal health (same health criteria apply as used in well-baby clinics when a child receives a vaccination, e.g. also children with small increases in temperature (<38.5C) or cold are seen as children with normal health);
2. The parents/legally representatives have to be willing and able to allow their child to participate in the trial according to the described procedures;
3. Presence of a signed informed consent (the parents/legally representatives have given written informed consent after receiving oral and written information);
4. PCV13 group: The children are 2 months old (+/-2 weeks), have not received any vaccinations and will receive all vaccinations (DTaP-IPV-Hib-HepB and PCV13) by the study team;
5. PCV10 group: The children are 4-6 months old and have received three DTaP-IPV-Hib-HepB and PCV10 vaccinations according to the 3+1 schedule of the Dutch NIP*.

*The Dutch NIP 3+1 schedule: All children born as of August 1st 2011 will receive Synflorix (PCV10) and DTaP-IPV-Hib-HepB vaccinations, at the age of 2, 3 4 and 11 months of age.
- Exclusion criteria1. PCV13 group: Previous vaccinations with PCV7 or PCV10;
2. PCV10 group: Previous vaccinations with PCV7 or PCV13;
3. PCV10 group: Vaccinations using a schedule that differs from the Dutch 3+1 schedule;
4. Presence of a serious disease that requires medical care that can interfere with the results of the study;
5. Known or expected allergy/hypersensitivity against one of the vaccine ingredients;
6. Known or suspected immunological disorder;
7. Previously administration of plasma products (including immunoglobulin), within three months of study enrolment;
8. Presence of bleeding disorders;
9.Communication problems that interfere with the trial;
10. Prematurity (<37 weeks after gestation).
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 25-okt-2011
- planned closingdate1-dec-2012
- Target number of participants160
- Interventions1. Pneumococcalpolysaccharide conjugate vaccine (13-valent, adsorbed) (Prevenar-13), 0.5 ml via intramuscular injection at 2, 3, 4 and 11 months;
2. Pneumococcal polysaccharide conjugate vaccine (adsorbed) (Synflorix), 0.5 ml via intramuscular injection at 2, 3, 4 and 11 months.
- Primary outcome1. Cellular immune response (Plasma B cells and memory B cells) immediately before and 7-9 days after the booster at 11-months of age;
2. Humoral immune response (antibody concentrations and geometric mean concentrations (GMT)) at 12 months of age.
- Secondary outcome1. Opsonophagocytoses immediately before and 7-9 days after the booster at 11-months of age;
2. Avidity at 5, 8, immediately before and 7-9 days after the booster at 11-months and at 12 months of age;
3. Antibody concentrations and geometric mean concentrations (GMT) at 5, 8, immediately before and 7-9 days after the booster at 11-months and at 12 months of age;
4. Kinetics of antibody concentrations and geometric mean concentrations (GMT) over time (at 5, 8, 11 and 12 months of age);
5. DTaP-HIb antibody concentrations and geometric mean concentrations (GMT) at 5, 8, 11 and 12 months of age.
- Timepoints1. Humoral response: Month 5, 8, 11 (pre-booster) and 12 (post-booster);
2. Cellular response: Month 11 (pre-booster) and month 11 + 7/9 days (post-booster).
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIES Riet Jongerius
- CONTACT for SCIENTIFIC QUERIES Alienke Wijmenga-Monsuur
- Sponsor/Initiator National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control (CIb)
- Funding
(Source(s) of Monetary or Material Support)
Ministry of Health, Welfare and Sports
- PublicationsN/A
- Brief summaryStreptococcus pneumonia (SP) is an important cause of morbidity and mortality worldwide, with the highest incidence of disease among children < 2 years of age. Streptococcus pneumonia consisting of > 90 known different serotypes, of which a limited number of about 20 serotypes are known to cause invasive pneumococcal disease (IPD).
Prevenar®, a seven-valent pneumococcal conjugate vaccine (PCV7) was first introduced in the Netherlands immunization program (NIP) for children born after April 2006. It confers protection against serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. It has been introduced in the NIP for vaccination at 2, 3, 4 and 11 months of age. Recently in 2009, two new vaccines were registered, which can in due time replace PCV7 in the NIP. All children born after March 2011 will receive Synflorix®, a ten-valent pneumococcal conjugate vaccine (PCV10) which confers protection against three additional serotypes. Prevenar-13®, a thirteen-valent pneumococcal conjugate vaccine (PCV13) confers protection against another three extra serotypes, but is not implemented in the NIP. The current study in combination with our previous KOKKI (cellular immunogenicity after PCV7 vaccination) and PIM (comparison of 4 different PCV13 vaccination schedules based on humoral immunogenicity) study can give information on the best vaccination strategy for pneumococcal vaccination. The outcomes of this trial will provide data on the humoral and cellular immune response of PCV10 and PCV13.
- Main changes (audit trail)
- RECORD15-sep-2011 - 21-okt-2011


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl